Swiss Life Sciences Stock News

St. Galler Kantonalbank (SWX:SGKN) reported its half year 2026 results with net interest income of CHF 190.17 million and net income of CHF 119.87 million, compared with CHF 184.92 million and CHF 114.1 million a year earlier. See our latest analysis for St. Galler Kantonalbank. St. Galler Kantonalbank’s recent half year 2026 earnings release comes after a steady share price gain, with the year to date share price return of 8.5% and a 1 year total shareholder return of 30.13%, suggesting...

Galenica AG recently reported past half-year 2026 results, with sales rising to CHF 2,136.45 million and revenue to CHF 2,143.28 million, while net income decreased to CHF 66.35 million and earnings per share eased compared with the prior year period. Despite the softer profitability, management confirmed its 2026 outlook for consolidated net sales growth of 5.7% and EBIT growth between 6% and 8%, underscoring confidence in the business trajectory. With Galenica confirming its 2026 earnings...

Market reaction to mixed half year performance Huber+Suhner (SWX:HUBN) reported half year 2026 results with sales at CHF 457.4 million and net income at CHF 34.75 million. Earnings per share were CHF 1.88, with sales higher and profit measures softer compared with the previous year. See our latest analysis for Huber+Suhner. Since the latest half year results on 14 August 2026, Huber+Suhner’s share price has been under pressure, with a 7 day share price return down 15.17% and 90 day share...

SGS (SWX:SGSN) is in focus after Allonnia launched a centralized pilot program at SGS's Lakefield facility, giving mining companies a simpler path to test D-Solve biological impurity removal technology. See our latest analysis for SGS. At a share price of CHF93.2, SGS has seen a 6.51% 90 day share price return and a 14.46% 1 year total shareholder return, which points to gradually improving momentum around the stock despite recent short term softness. If this kind of specialty metals and...

Half year earnings put Berner Kantonalbank stock in focus Berner Kantonalbank (SWX:BEKN) is back on investors’ radar after half year 2026 earnings showed net income of CHF 82.65 million on net interest income of CHF 191.82 million, prompting fresh attention on the stock’s recent performance. See our latest analysis for Berner Kantonalbank. The half year earnings update appears to have arrived during a strong run for Berner Kantonalbank, with the share price at CHF 380.50 and a year to date...

Sunrise Communications stock came into today looking bruised, with the share price drifting down roughly 3% over the past month and about 3% over the last quarter. The long term pitch around a cheap telecom with a turnaround story met some hard numbers in the latest release. Revenue for the last twelve months sat at CHF 2.98b while the company still reported a loss from continuing operations and negative earnings per share. The real headline is not growth but pressure. Profitability remains...

Implenia stock closed at CHF67.60, capping a strong 90 day run, yet the real story sits in the pressure on profitability. The construction and engineering group is still producing earnings and cash flows that keep the shares on a P/E of 14.9x, below both the European sector and peers, but net profit margins have tightened. For short term traders the recent share price strength may feel reassuring. Long term holders will focus more on whether management can protect margins while pursuing...

HIAG Immobilien Holding (SWX:HIAG) has drawn investor focus after reporting half year 2026 results that include CHF 158.63 million in revenue and CHF 84.97 million in net income, alongside higher earnings per share. See our latest analysis for HIAG Immobilien Holding. Alongside these half year results and fresh CHF 100 million green bond issuance, HIAG Immobilien Holding has seen mixed momentum, with the share price up 7.01% year to date but down 8.35% over 30 days, while the 1 year total...

DocMorris stock closed at CHF10.00 on the day of its latest earnings, capping a volatile few months that included a sharp rebound over the past quarter. The market has been treating DocMorris as a high growth, online pharmacy bet. The headline from the latest numbers is more sobering. Revenue over the last twelve months reached about CHF1.1b, yet the company still reported a sizeable loss from continuing operations and a loss per share in the mid single digit CHF range. The expectation gap is...

Emmi stock closed at CHF830 on the day of its earnings release, capping a choppy spell that left the shares down about 4% over the past week and 7% over the past month. The market is clearly wary. The results themselves point to a different tension. Earnings over the last twelve months grew faster than the company’s own five year trend; however, the net profit margin edged down to 4.8% from 5.1%, and investors still have to weigh that against a high debt load. Like the earnings growth at Emmi...

BKW shareholders came into today already bruised, with the stock down about 14% over three months and closing at CHF128.30 just as the latest earnings landed. The immediate question is whether that slide reflects weakening profitability or a market that has fixated on the wrong part of the story. The key plot line in this earnings release is margin pressure. Net profit margin has slipped from 13.4% to 8.3%, while first half EBIT dropped to CHF262.7m even as net profit reached CHF217.6m and...

Straumann Holding stock closed at CHF97.22 on the day its latest figures landed, well below an internal discounted cash flow estimate of CHF160.06. The market has been trimming exposure in recent weeks; yet the fresh numbers highlight a different story. Earnings sit on a compressed 13.7% net profit margin after a CHF136.0m one off loss in the last twelve months, while the P/E of 43.5x prices Straumann as a premium dental equipment play. The key question for you is whether that margin squeeze...

Geberit stock went into these results priced for quality plumbing perfection, trading on a rich 30.8x P/E and already up double digits over the past three months. The company then delivered what the thesis demands. Earnings grew over the last twelve months, margins stayed high with a 19.2% net profit margin, and management reaffirmed guidance for mid single digit sales and earnings growth. The twist for investors now is not whether Geberit is executing. Instead, it is whether this level of...

SIG Group (SWX:SIGN) abruptly replaced CEO Mikko Keto with former CFO Ann-Kristin Erkens less than six months into Keto’s tenure, raising questions about leadership stability despite reaffirmed guidance and an upcoming Capital Markets Day. See our latest analysis for SIG Group. For context, SIG Group’s 1 day share price return of 1.31% comes after a sharp 7 day share price decline of 14.20%. The 90 day share price return of 11.99% and year to date share price return of 14.92% contrast with a...

Medartis Holding stock has been on a tear, with a 3 month gain of about 22% heading into today, and the valuation now up at roughly 78x trailing P/E. The H1 2026 earnings print gave that optimism a fresh stress test. Revenue reached CHF 160.8m and the core EBITDA margin sat at 18%, which is the real headline. The market has been paying a rich multiple for growth and profitability, so this margin performance now becomes the key lens for both short term traders and long term holders. Love...

Basilea Pharmaceutica stock closed at CHF62.50 on Wednesday after a strong run over the past month. Yet the real story sits in the earnings print that just landed. The headline is a cleaner, more profitable anti infectives business, with H1 2026 revenue of CHF118.996m translating into net income of CHF27.946m and basic earnings per share of CHF2.26. The market is reacting to a short burst of momentum. Long term holders are now weighing that profit profile against a modest growth outlook and a...

PSP Swiss Property closed at CHF142.30 on Wednesday, capping a three month drift lower even as fresh Q2 numbers put eye catching profits on the table. The market reaction looks muted compared with the headline story. Net income excluding extra items reached CHF171.75m on CHF236.46m of revenue, helped by sizeable valuation gains and disposals that are hard to treat as everyday earnings power. That tension between a rich profit print today and softer multi year forecasts is the real hinge for...

Phoenix Mecano stock closed at CHF443 today, only slightly above where it was trading a month ago, even after investors digested fresh half year numbers. The headline from these results is not the modest revenue move. It is the sharp jump in operating profitability, with earnings before interest and tax up 23.5% on the back of stronger margins in the industrial units. Over a longer horizon the story shifts to valuation. The stock trades on a trailing P/E of 14x, while peers sit much higher...

SKAN Group stock has been on a tear into this earnings print, closing at CHF62.70 and logging a roughly 32% gain over the past three months. That kind of run sets a high bar for a specialised pharma equipment supplier. The headline from H1 is clear. SKAN Group delivered a sharp reset in profitability with net profit of CHF5.4m and an EBITDA margin of 9.3% on CHF164.5m of net sales. Order intake of CHF247.6m and a CHF442m backlog reflect why the growth story still commands a premium P/E...

Novartis stock has delivered a strong 88.5% return over the past five years, and the valuation checks now point to a company that looks undervalued on market multiples but not as a straightforward bargain across every metric. Over the past 5 years, Novartis has returned 88.5%, which puts recent short term ups and downs into the context of a solid multi year share price performance. Protecting cash flows from key products such as Entresto, supported by the recent UK court win on its patent,...

As European markets navigate the complexities of geopolitical tensions and fluctuating energy prices, the pan-European STOXX Europe 600 Index has seen a slight decline, reflecting mixed investor sentiment. In this environment, identifying stocks that are trading below their estimated fair value can offer opportunities for investors seeking to capitalize on resilient regional economic data and solid corporate earnings.

As the European markets navigate a landscape marked by resilient economic data and geopolitical uncertainties, investors are increasingly exploring diverse opportunities. Penny stocks, often seen as relics of past market eras, continue to offer intriguing potential for those willing to look beyond the larger indices. These smaller or newer companies can provide a unique mix of affordability and growth potential when paired with strong financials, making them an area worth watching for...

SKAN Group (SWX:SKAN) has drawn fresh attention after reporting H1 2026 net income of CHF 4.81 million, compared with a net loss of CHF 8.9 million a year earlier. See our latest analysis for SKAN Group. The swing back to profit in H1 2026 has coincided with a clear shift in sentiment toward SKAN Group, with a 90 day share price return of 26.07% and a year to date gain of 13.03%, even though the 1 year total shareholder return is still down 11.66%. If SKAN Group’s rebound has you thinking...

Sandoz Group AG recently announced a collaboration agreement with Shanghai Henlius Biotech, Inc. to develop, manufacture and commercialise up to 10 biosimilars, including proposed versions of cetuximab, evolocumab and belimumab, with Henlius handling development and manufacturing and Sandoz holding commercial rights outside China under a milestones-based deal of up to US$322 million. This partnership lifts Sandoz’s biosimilar pipeline from 39 assets with potential to reach up to 46,...